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When should we screen children
for hyperlipidemia?
With no clear medical treatment 
for childhood dyslipidemia,
screening provides little help
There is no clear evidence to support
screening children with or without familial
hypercholesterolemia for hypercholes-
terolemia. In an era where judicious use of
medical dollars is a must, screening for
hypercholesterolemia would also be cost-
prohibitive. Other than stressing exercise
and nutrition, there is no clear medical
treatment that is FDA-approved for 
dyslipidemia among children, so screening
would provide very little help in the 
management of this population.
Patients with a strong family history of
lipid disorders or familial hypercholes-
terolemia should have more directed 
education on cholesterol and their need to
treat in early adulthood; however, at this
time there is very little evidence to support
screening in this population. Aggressive
promotion of age-appropriate exercise and
a healthy lifestyle should be the thrust of
our intervention until more evidence-based
information shows that screening and 
treatment improves morbidity and mortality.
This Clinical Inquiry emphasizes the
need to do more research in pediatric
hypercholesterolemia, to better counsel our
patients not only in screening but ultimately
in earlier medical intervention.
Walter Foliaco, MD
Chesterfield Family Practice, Midlothian, Va
C L I N I C A L C O M M E N TA R Y
z Evidence summary
Screening for hyperlipidemia using total
cholesterol and low-density lipoprotein
(LDL) cholesterol is recommended for
adults after the age of 35 years for men
and 45 years for women.1 Younger adults
(men aged 20–35 and women aged 20–45)
should be screened for lipid disorders if
they have other risk factors for CVD.1
E V I D E N C E - B A S E D A N S W E R
Children should be screened for 
hyperlipidemia when there is a history 
of familial hypercholesterolemia 
(strength of recommendation [SOR]: C).
No clear evidence supports screening 
all children or just those with family 
history of cardiovascular disease (CVD) 
or hyperlipidemia (SOR: C).
Children with heterozygous familial
hypercholesterolemia, an autosomal domi-
nant disorder with a prevalence of 1 in 
500, are at increased risk of cardiovascular
morbidity and mortality in adulthood. One
quarter of males with familial hyper-
cholesterolemia suffer fatal coronary 
heart disease (CHD) by age 50 years.2
The use of statins by children with
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familial hypercholesterolemia for up to 2
years is safe and lowers LDL cholesterol.3
Longer use by children has not been 
studied, so no comment can be made
about long-term safety and decreased
CHD morbidity and mortality.
One systematic review and cost-effec-
tiveness analysis investigated the appropri-
ateness and cost-effectiveness of screening
methods for familial hypercholesterolemia
beginning at the age of 16 years.4 The
authors identified potential screening
strategies from 6 cross-sectional studies
and applied these to a decision analysis.
Screening of first-degree relatives of those
with familial hypercholesterolemia was
most effective in detecting cases of familial
hypercholesterolemia (number needed to
screen [NNS] = 3; cost per case detected =
$232; cost per life-year gained = $5397). 
Universal screening of all 16-year-olds
was also cost-effective (cost per life-year
gained = $4839), but resulted in a much
larger NNS and cost of detection
(NNS=1365, cost per case detected =
$16,999). The authors concluded that case
finding through screening of first-degree
relatives was the most cost-effective strate-
gy overall.
In contrast to children affected with
familial hypercholesterolemia, the relation-
ship of blood cholesterol levels in children
without familial hypercholesterolemia to
CHD later in life has not been established.
A paucity of data exists that links lowering
of cholesterol in childhood with reduced
CHD morbidity and mortality in adult-
hood. Therefore, the benefits of detecting
and treating childhood hyperlipidemia
without familial hypercholesterolemia are
not known. Despite the lack of patient-
oriented outcomes research in this area, 
2 guidelines recommend screening all 
children for hyperlipidemia.5,9
Three studies investigated the use of
various recommended screening indicators
in identifying children with hyperlipi-
demia. The first was a control cohort from
a case-control study that applied the
National Cholesterol Education Program
(NCEP) guidelines for screening in chil-
dren5 to 501 US males less than 20 years
old, and examined the effectiveness of
using the recommended 2 major screening
indicators (family history of premature
cardiovascular disease and parent choles-
terol >240 mg/dL) plus 5 discretionary
indicators (high-fat/high-cholesterol diet,
hypertension, obesity, smoker, steroid/
medication).6 If all major and discretionary
indicators were applied to the cohort, 96%
of the children with LDL greater than 130
mg/dL were identified.  However, the indi-
vidual positive predictive values (PPV;
probability of having LDL >130 when a
child had a screening indicator) ranged
from 6.8% to 20.6%.
The 2 other studies used a cross-
sectional design to evaluate family history
of premature cardiovascular disease and
hyperlipidemia screening indicators in
4183 grade-school children in Taiwan7 and
2217 youths in Quebec.8 Family history
performed poorly as a mechanism for
identifying children with hypercholes-
terolemia (total cholesterol >200 mg/dL;
LDL >130 mg/dL) (PPV <12.5%7,
PPV=7.7%8). More than 75% of the chil-
dren in the Taiwan study would have been
missed using family history as a screen.
Both studies concluded that family history
as a screening indicator is insensitive and
inaccurate, and no more useful than gener-
al population screening. 
Recommendations from others
Neither the American Academy of Family
Physicians or the US Preventive Services
Task Force makes a recommendation
about screening for hyperlipidemia in this
age group. 
The American Academy of Pediatrics
recommends screening children aged 2
years or older whose parents or grand-
parents had coronary atherosclerosis at
age 55 or younger (defined by diagnostic
coronary arteriography, myocardial infarc-
tion, angina pectoris, peripheral vascular
disease, cerebrovascular disease, or sudden
cardiac death). They also advocate screen-
ing children of a parent with an elevated
blood cholesterol level (total cholesterol
Children with 
a family history 
of lipid disorders
should have more
directed education
on cholesterol, but
little evidence 
supports screening
this population
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240 mg/dL or higher) and those whose
parental history is unobtainable.9 
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